A
3.05
0.00 (0.00%)
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看涨 |
| Biotechnology (全球的) | 混合的 | 看涨 | |
| 股票 | ARS Pharmaceuticals, Inc. | 混合的 | 混合的 |
AIStockmoo 评分
| 分析师共识 | 0.0 |
| 内部交易活动 | NA |
| 价格波动 | 3.0 |
| 技术平均移动指标 | 5.0 |
| 技术振荡指标 | -2.5 |
| 相对估值 | NA |
| 财务健康 | -0.1 |
| 宏观环境 | -1.3 |
| AI Insight | NA |
| AI Technical | NA |
| 平均 | 0.75 |
|
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Core |
| 内部持股比例 | 16.93% |
| 机构持股比例 | 80.28% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Tyro Capital Management Llc | 30 Jun 2026 | 4,459,337 |
| Sr One Capital Management, Lp | 30 Jun 2026 | 4,012,903 |
该时间范围内无数据。
该时间范围内无数据。
投资组合